Zoetis Inc. (0M3Q.L)
USD 157.33
(0.66%)
USD 157.33
(0.66%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.83 Billion USD | 3.7% |
| 2022 | 5.62 Billion USD | 2.8% |
| 2021 | 5.47 Billion USD | 18.51% |
| 2020 | 4.61 Billion USD | 8.2% |
| 2019 | 4.26 Billion USD | 9.04% |
| 2018 | 3.91 Billion USD | 10.82% |
| 2017 | 3.53 Billion USD | 9.62% |
| 2016 | 3.22 Billion USD | 6.44% |
| 2015 | 3.02 Billion USD | -1.34% |
| 2014 | 3.06 Billion USD | 6.09% |
| 2013 | 2.89 Billion USD | 4.29% |
| 2012 | 2.77 Billion USD | 7.44% |
| 2011 | 2.58 Billion USD | 20.72% |
| 2010 | 2.13 Billion USD | 27.11% |
| 2009 | 1.68 Billion USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.65 Billion USD | 9.8% |
| 2024 Q1 | 1.51 Billion USD | 4.28% |
| 2024 Q3 | 1.68 Billion USD | 1.75% |
| 2023 Q2 | 1.57 Billion USD | 11.4% |
| 2023 FY | 5.83 Billion USD | 3.7% |
| 2023 Q1 | 1.41 Billion USD | 1.8% |
| 2023 Q3 | 1.51 Billion USD | -3.81% |
| 2023 Q4 | 1.44 Billion USD | -4.3% |
| 2022 Q1 | 1.41 Billion USD | 3.66% |
| 2022 FY | 5.62 Billion USD | 2.8% |
| 2022 Q4 | 1.38 Billion USD | -0.57% |
| 2022 Q3 | 1.39 Billion USD | -2.24% |
| 2022 Q2 | 1.42 Billion USD | 0.71% |
| 2021 Q4 | 1.36 Billion USD | -2.64% |
| 2021 Q2 | 1.38 Billion USD | 4.39% |
| 2021 FY | 5.47 Billion USD | 18.51% |
| 2021 Q3 | 1.4 Billion USD | 1.74% |
| 2021 Q1 | 1.32 Billion USD | 9.62% |
| 2020 Q4 | 1.2 Billion USD | -2.74% |
| 2020 FY | 4.61 Billion USD | 8.2% |
| 2020 Q1 | 1.07 Billion USD | -6.03% |
| 2020 Q2 | 1.09 Billion USD | 2.05% |
| 2020 Q3 | 1.24 Billion USD | 13.04% |
| 2019 Q1 | 937 Million USD | -8.14% |
| 2019 Q4 | 1.14 Billion USD | 3.53% |
| 2019 FY | 4.26 Billion USD | 9.04% |
| 2019 Q3 | 1.1 Billion USD | 2.13% |
| 2019 Q2 | 1.08 Billion USD | 15.47% |
| 2018 Q2 | 968 Million USD | 5.33% |
| 2018 Q1 | 919 Million USD | -8.37% |
| 2018 FY | 3.91 Billion USD | 10.82% |
| 2018 Q4 | 1.02 Billion USD | 1.29% |
| 2018 Q3 | 1 Billion USD | 4.03% |
| 2017 Q3 | 912 Million USD | 10.01% |
| 2017 Q1 | 788 Million USD | -2.6% |
| 2017 FY | 3.53 Billion USD | 9.62% |
| 2017 Q4 | 1 Billion USD | 9.98% |
| 2017 Q2 | 829 Million USD | 5.2% |
| 2016 Q3 | 831 Million USD | 2.72% |
| 2016 FY | 3.22 Billion USD | 6.44% |
| 2016 Q1 | 773 Million USD | -0.64% |
| 2016 Q2 | 809 Million USD | 4.66% |
| 2016 Q4 | 809 Million USD | -2.65% |
| 2015 FY | 3.02 Billion USD | -1.34% |
| 2015 Q4 | 778 Million USD | -1.89% |
| 2015 Q3 | 793 Million USD | 6.02% |
| 2015 Q2 | 748 Million USD | 5.65% |
| 2015 Q1 | 708 Million USD | -14.6% |
| 2014 FY | 3.06 Billion USD | 6.09% |
| 2014 Q4 | 829 Million USD | 6.83% |
| 2014 Q3 | 776 Million USD | 4.16% |
| 2014 Q1 | 718 Million USD | -8.88% |
| 2014 Q2 | 745 Million USD | 3.76% |
| 2013 Q1 | 688 Million USD | -7.4% |
| 2013 Q2 | 698 Million USD | 1.45% |
| 2013 Q3 | 718 Million USD | 2.87% |
| 2013 Q4 | 788 Million USD | 9.75% |
| 2013 FY | 2.89 Billion USD | 4.29% |
| 2012 Q4 | 743 Million USD | 12.58% |
| 2012 Q3 | 660 Million USD | -7.82% |
| 2012 FY | 2.77 Billion USD | 7.44% |
| 2012 Q2 | 716 Million USD | 9.48% |
| 2012 Q1 | 654 Million USD | -7.63% |
| 2011 FY | 2.58 Billion USD | 20.72% |
| 2011 Q1 | 602 Million USD | 0.0% |
| 2011 Q2 | 620 Million USD | 2.99% |
| 2011 Q3 | 651 Million USD | 5.0% |
| 2011 Q4 | 708 Million USD | 8.76% |
| 2010 FY | 2.13 Billion USD | 27.11% |
| 2009 FY | 1.68 Billion USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -263286.005% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -1931688.079% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 6946.132% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -33585.548% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 1863997.764% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -39334.906% |
| Imunon, Inc. | -720 Thousand USD | 810372.151% |
| Dynavax Technologies Corporation | 182.11 Million USD | -3103.435% |
| Editas Medicine, Inc. | -99.52 Million USD | 5961.667% |
| FibroGen, Inc. | 128.9 Million USD | -4425.849% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 61086.828% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 1925512.541% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -215.795% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -433.764% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -1013.907% |
| Verastem, Inc. | -62 Thousand USD | 9409777.419% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 32.218% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 12971.484% |
| Homology Medicines, Inc. | -7.22 Million USD | 80802.725% |
| Nektar Therapeutics | 53.47 Million USD | -10809.159% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 1998045.205% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 29715.717% |
| Perrigo Company plc | 1.68 Billion USD | -247.179% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -7884.453% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 78.005% |
| Illumina, Inc. | 2.74 Billion USD | -112.609% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 61.679% |
| IQVIA Holdings Inc. | 5.23 Billion USD | -11.357% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -57995.997% |
| Waters Corporation | 1.76 Billion USD | -231.253% |
| Biogen Inc. | 7.3 Billion USD | 20.106% |
| Evolus, Inc. | 140.52 Million USD | -4051.545% |
| Adicet Bio, Inc. | -6.09 Million USD | 95770.712% |
| bluebird bio, Inc. | -4.03 Million USD | 144864.268% |
| Geron Corporation | -123.5 Million USD | 4823.772% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -284.35% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -1511.469% |
| Myriad Genetics, Inc. | 476.4 Million USD | -1124.601% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 1562.911% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -168.963% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 18818.12% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -206.348% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 48.378% |
| Agilent Technologies, Inc. | 3.46 Billion USD | -68.369% |
| OPKO Health, Inc. | 318.12 Million USD | -1733.859% |
| Exelixis, Inc. | 1.75 Billion USD | -231.918% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -1125.903% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -2285.753% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -649.376% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -816.011% |
| Blueprint Medicines Corporation | 236.58 Million USD | -2365.932% |
| Insmed Incorporated | 239.63 Million USD | -2334.536% |
| TG Therapeutics, Inc. | 219.1 Million USD | -2562.614% |
| Incyte Corporation | 3.44 Billion USD | -69.561% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -1596.423% |